On August 22, 2022 TC Biopharm (Holdings) PLC ("TC Biopharm" or the "Company") (NASDAQ: TCBP) (NASDAQ: TCBPW), a clinical stage biotechnology company developing platform allogeneic gamma-delta T cell therapies for cancer treatment, reported that Chief Executive Officer, Bryan Kobel will present a company overview at the H.C. Wainwright 24th Annual Global Investment Conference, on Monday, September 12th at 7:00 am (Press release, TC Biopharm, AUG 22, 2022, https://www.prnewswire.com/news-releases/tc-biopharm-to-present-at-the-hc-wainwright-24th-annual-global-investment-conference-301609516.html [SID1234618555]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

A webcast of the presentation will be available on the Investor Relations page of TC BioPharm’s website. For more information or schedule a 1X1 meeting with management, please visit; View Source